Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- ezetimibe
- zavegepant
Interactions between your drugs
ezetimibe zavegepant
Applies to: ezetimibe, zavegepant
GENERALLY AVOID: Coadministration with inhibitors of the organic anion transporting polypeptide (OATP) 1B3 hepatic uptake transporter and/or the hepatic bile acid uptake transporter sodium taurocholate co-transporting polypeptide (NTCP) may significantly increase the plasma concentrations and effects of zavegepant, which is a substrate of these transporters. When single-dose oral zavegepant (100 mg) was administered with the OATP 1B3 and NTCP inhibitor and strong CYP450 3A4 inducer, rifampin, at steady state, zavegepant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.2- and 2.3-fold, respectively.
MANAGEMENT: Concomitant use of zavegepant with OATP 1B3 and/or NTCP inhibitors should generally be avoided.
References (4)
- (2023) "Product Information. Zavzpret (zavegepant)." Pfizer U.S. Pharmaceuticals Group
- Dong Z, Ekins S, Polli J.E (2013) "Structure activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate co-transporting polypeptide (NTCP)" Mol Pharm, 10, p. 1008-1019
- Solvo Biotechnology (2023) Human Transporters: NTCP (sodium/taurocholate cotransporting polypeptide) https://www.solvobiotech.com/transporters/ntcp
- (2022) "Product Information. HEPCLUDEX (bulevirtid)." Gilead Sciences Sweden AB, 1
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Leqvio
Leqvio is used in adults with primary hyperlipidemia to reduce low-density lipoprotein (LDL-C) ...
Repatha
Repatha is used to lower high cholesterol alongside dietary changes and to reduce the risk of major ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Lipitor
Lipitor is used to treat high cholesterol. Learn about side effects, interactions and indications.
Crestor
Crestor (rosuvastatin) is used to treat high cholesterol and high triglycerides in the blood ...
Zetia
Zetia (ezetimibe) is used to treat high cholesterol. Includes Zetia side effects, interactions and ...
Zocor
Zocor (simvastatin) reduces low-density lipoprotein cholesterol and total cholesterol in the blood ...
Praluent
Praluent (alirocumab) is an injectable medicine that is given under your skin which may be used in ...
Nexletol
Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.